Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries

Hypertension

Volumn 50, Issue 1, 2007, Pages 110-115

  Sivieri Jr , Disney O ^a   Bispo Da Silva, Luiz B ^a   Oliveira, Eduardo B ^a   Resende, Angela C ^a   Salgado, Maria Cristina O ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ACE activity; ACE inhibitor; Bradykinin; Endopeptidases; Kininase I

Indexed keywords

2 MERCAPTOMETHYL 3 GUANIDINOETHYLTHIOPROPANOIC ACID; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PHENYLEPHRINE; PHOSPHORAMIDON; RAMIPRILAT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY PERFUSION; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLIP; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; ISOLATED ARTERY; KIDNEY ARTERY; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; RAT; VASODILATATION;

3-MERCAPTOPROPIONIC ACID; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; BRADYKININ; DRUG SYNERGISM; ENZYME INHIBITORS; GLYCOPEPTIDES; HYPERTENSION; LYSINE CARBOXYPEPTIDASE; MALE; MESENTERIC ARTERIES; METALLOENDOPEPTIDASES; NEPRILYSIN; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTEASE INHIBITORS; RATS; RATS, WISTAR; VASODILATION; VASODILATOR AGENTS;

EID: 34250817581     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.106.085761     Document Type: Article

References (32)

1. Haddy FJ, Emerson TE Jr, Scott JB, Daugherty RM Jr. The effect of the kinins on the cardiovascular system. In: Erdös EG, ed. Handbook of Experimental Pharmacology, Bradykinin, Kallidin and Kallikrein. Berlin, Germany: Springer-Verlag; 1970:362-384.
2. Altura BM, Chand N. Bradykinin-induced relaxation of renal and pulmonary arteries is dependent upon intact endothelial cell. Br J Pharmacol. 1981;74:10-11.
3. Resende AC, Ballejo G, Salgado MC. Role of non-nitric oxide non-prostaglandin endothelium-derived relaxing factor(s) in bradykinin vasodilation. Braz J Med Biol Res. 1998;31:1229-1235.
4. Erdös EG, Skidgel RA. Metabolism of bradykinin by peptidases in health and disease. In: Farmer SG, ed. The Kinin System. San Diego, CA: Academic; 1997:111-141.
5. Skidgel RA, Davis RM, Tan F. Human carboxypeptidase M. Purification and characterization of a membrane-bound carboxypeptidase that cleaves peptide hormones. J Biol Chem. 1989;264:2236-2241.
6. Roques BP, Noble F, Daugé V, Fournié-Zaluski M-C, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993;45:87-146.
7. Skidgel RA. Bradykinin-degrading enzymes: structure, function, distribution, and potential roles in cardiovascular pharmacology. J Cardiovasc Pharmacol. 1992;20(suppl 9):S4-S9.
8. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
9. Hecker M, Pörsti I, Bara AT, Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br J Pharmacol. 1994;111:238-244.
10. Minshall RD, Erdös EG, Vogel SM. Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. Am J Cardiol. 1997;80:132A-136A.
11. 2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res. 1997;81:848-856.
12. 2 kinin receptor within the plasma membrane of native endothelial cells. Circulation. 1999;99:2034-2040.
13. Dendorfer A, Wolfrum S, Schafer U, Stewart JM, Inamura N, Dominiak P. Potentiation of the vascular response to kinins by inhibition of myocardial kininases. Hypertension. 2000;35:32-37.
14. Tom B, Dendorfer A, de Vries R, Saxena PR, Jan Danser AH. Bradykinin potentiation by ACE inhibitors: a matter of metabolism. Br J Pharmacol. 2002;137:276-284.
15. Leite R, Salgado MCO. Increased vascular formation of angiotensin II in one-kidney, one clip hypertension. Hypertension. 1992;19:575-581.
16. Yu H, Rakugi H, Higaki J, Morishita R, Mikami H, Ogihara T. The role of activated vascular angiotensin II generation in vascular hypertrophy in one-kidney, one clip hypertensive rats. J Hypertens. 1993;11:1347-1355.
17. Cunha V, Salgado HC, Salgado MCO. Enalapril prevents aortic hyperreactivity and remodeling in one-kidney, one-clip hypertensive rats without reducing arterial pressure. Clin Exp Pharmacol Physiol. 2000;27:474-479.
18. Salgado MCO, Caldo H, Rodrigues MCG. Effect of bradykinin on isolated mesenteric arteries of the rat. Hypertension. 1992;(suppl II): II-251-II-254.
19. Santos CF, Oliveira EB, Salgado MCO, Greene AS. Molecular cloning and sequencing of the cDNA for rat mesenteric arterial bed elastase-2, an angiotensin II-forming enzyme. J Cardiovasc Pharmacol. 2002;39: 628-635.
20. Santos CF, Caprio MAV, Oliveira EB, Salgado MCO, Schippers DN, Munzenmaier DH, Greene AS. Functional role, cellular source, and tissue distribution of rat elastase-2, an angiotensin II-forming enzyme. Am J Physiol Heart Circ Physiol. 2003;285:H775-H783.
21. Oliveira EB, Salgado MCO, Turner AJ. A survey of vasoactive peptide metabolizing enzymes in the rat mesenteric arterial bed perfusate. Biochem Pharmacol. 1991;42:1897-1904.
22. Ura N, Carretero OA, Erdos EG. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int. 1987;32:507-513.
23. Smits GJ, McGraw DE, Trapani AJ. Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: renal effects. Am J Physiol. 1990;258:F1417-F1424.
24. Campbell DJ, Anastasopoulos F, Duncan A-M, James GM, Kladis A, Briscoe TA. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther. 1998;287:567-577.
25. Rioli V, Kato A, Portaro FC, Cury GK, te Kaat K, Vincent B, Checler F, Camargo AC, Glucksman MJ, Roberts JL, Hirose S, Ferro ES. Neuropeptide specificity and inhibition of recombinant isoforms of the endopeptidase 3.4.24.16 family: comparison with the related recombinant endopeptidase 3.4.24.15. Biochem Biophys Res Commun. 1998;250:5-11.
26. Smith AI, Lew RA, Shrimpton CN, Evans RG, Abbenante G. A novel stable inhibitor of endopeptidases EC 3.4.24.15 and 3.4.24.16 potentiates bradykinin-induced hypotension. Hypertension. 2000;35:626-630.
27. Norman MU, Reeve SB, Dive V, Smith AI, Lew RA. Endopeptidases 3 4.24.15 and 24.16 in endothelial cells: potential role in vasoactive peptide metabolism. Am J Physiol Heart Circ Physiol. 2003;284:H1978-H1984.
28. Nakamura T, Prewitt RL. Alteration of endothelial function in arterioles of renal hypertensive rats at two levels of vascular tone. J Hypertens. 1992;10:621-627.
29. Stankevicius E, Martinez AC, Mulvany MJ, Simonsen U. Blunted acetylcholine relaxation and nitric oxide release in arteries from renal hypertensive rats. J Hypertens. 2002;20:1571-1579.
30. Wirth KJ, Linz W, Wiemer G, Scholkens BA. Differences in acetylcholine- and bradykinin-induced vasorelaxation of the mesenteric vascular bed in spontaneously hypertensive rats of different ages. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:38-43.
31. Vanhoutte PM. Endothelial dysfunction in hypertension. J Hypertens Suppl. 1996;14:S83-S93.
32. Chen Z, Deddish PA, Minshall RD, Becker RP, Erdos EG, Tan F. Human ACE and bradykinin B2 receptors form a complex at the plasma membrane. FASEB J. 2006;20:2261-2270.